Enhanced specific antitumor immunity of dendritic cells transduced with the glypican 3 gene and co-cultured with cytokine-induced killer cells against hepatocellular carcinoma cells

Wang,Yuliang; Wang,Yinlong; Mu,Hong; Liu,Tao; Chen,Xiaobo; Shen,Zhongyang

doi:10.3892/mmr.2015.3239

Enhanced specific antitumor immunity of dendritic cells transduced with the glypican 3 gene and co-cultured with cytokine-induced killer cells against hepatocellular carcinoma cells

Authors:
- Yuliang Wang
- Yinlong Wang
- Hong Mu
- Tao Liu
- Xiaobo Chen
- Zhongyang Shen
View Affiliations

Affiliations: Department of Clinical Laboratory Medicine, Tianjin First Central Hospital, Key Laboratory for Critical Care Medicine of the Ministry of Health, Tianjin 300192, P.R. China, Department of Hernia and Abdominal Wall Surgery, Union Medicine Center, Tianjin 300121, P.R. China, Union Stem and Gene Engineering Co., Tianjin 300384, P.R. China
Published online on: January 22, 2015 https://doi.org/10.3892/mmr.2015.3239
Pages: 3361-3367
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dendritic cell (DC)‑based cancer immunotherapy requires an immunogenic tumor‑associated antigen and an effective therapeutic strategy. Glypican 3 (GPC3) is a valuable diagnostic marker and a potential therapeutic target in hepatocellular carcinoma (HCC). The present study investigated whether DCs transduced with the GPC3 gene (DCs‑GPC3) and co‑cultured with autologous cytokine‑induced killer cells (CIKs) may induce a marked specific immune response against GPC3‑expressing HCC cells in vitro and in vivo. Human DCs were transfected with a green fluorescent protein plasmid with GPC3 by nucleofection and then co‑cultured with autologous CIKs. Flow cytometry was used to measure the phenotypes of DCs and CIKs. The co‑cultured cells were harvested and incubated with HCC cells and the cytotoxicity of the CIKs was assessed by nonradioactive cytotoxicity assay. The anti-tumor activity of these effector cells was further evaluated using a nude mouse tumor model. The results demonstrated that DCs‑GPC3 significantly promoted the autologous CIKs differentiation, as well as anti‑tumor cytokine interferon‑γ secretion. In addition, DCs‑GPC3‑CIKs significantly enhanced the cytotoxic activity against GPC3‑expressing HepG2 cells, indicating a GPC3‑specific marked immune response against HCC cells. The in vivo data indicated that DCs‑GPC3‑CIKs exhibited significant HepG2 cell‑induced tumor growth inhibition in nude mice. The results of the present study provided a new insight into the design of personalizing adoptive immunotherapy for GPC3‑expressing HCC cells.

View Figures

View References

1	Schütte K, Bornschein J and Malfertheiner P: Hepatocellular carcinoma - epidemiological trends and risk factors. Dig Dis. 27:80–92. 2009. View Article : Google Scholar
2	Mittal S and El-Serag HB: Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 47(Suppl): S2–S6. 2013. View Article : Google Scholar : PubMed/NCBI
3	Vivarelli M, Montalti R and Risaliti A: Multimodal treatment of hepatocellular carcinoma on cirrhosis: An update. World J Gastroenterol. 19:7316–7326. 2013. View Article : Google Scholar : PubMed/NCBI
4	Nishikawa H, Arimoto A, Wakasa T, et al: Effect of transcatheter arterial chemoembolization prior to surgical resection for hepatocellular carcinoma. Int J Oncol. 42:151–160. 2013.
5	Greten TF, Duffy AG and Korangy F: Hepatocellular carcinoma from an immunologic perspective. Clin Cancer Res. 19:6678–6685. 2013. View Article : Google Scholar : PubMed/NCBI
6	Xie F, Zhang X, Li H, et al: Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. PLoS One. 7:e428792012. View Article : Google Scholar : PubMed/NCBI
7	Raval RR, Sharabi AB, Walker AJ, et al: Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer. 2:142014. View Article : Google Scholar : PubMed/NCBI
8	Weng DS, Zhou J, Zhou QM, et al: Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother. 31:63–71. 2008. View Article : Google Scholar
9	Yu X, Xia W, Zhang T, et al: Enhanced cytotoxicity of IL-24 gene-modified dendritic cells co-cultured with cytokine-induced killer cells to hepatocellular carcinoma cells. Int J Hematol. 92:276–282. 2010. View Article : Google Scholar : PubMed/NCBI
10	Su S, Zhou H, Xue M, et al: Anti-tumor efficacy of a hepatocellular carcinoma vaccine based on dendritic cells combined with tumor-derived autophagosomes in murine models. Asian Pac J Cancer Prev. 14:3109–3116. 2013. View Article : Google Scholar : PubMed/NCBI
11	Palucka K and Banchereau J: Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 12:265–277. 2012. View Article : Google Scholar : PubMed/NCBI
12	Kantoff PW, Higano CS, Shore ND, et al: IMPACT Study Investigators: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 363:411–422. 2010. View Article : Google Scholar : PubMed/NCBI
13	Jiang J, Wu C and Lu B: Cytokine-induced killer cells promote antitumor immunity. J Transl Med. 11:832013. View Article : Google Scholar : PubMed/NCBI
14	Sangiolo D: Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer. 2:363–368. 2011. View Article : Google Scholar : PubMed/NCBI
15	O’Beirne J, Farzaneh F and Harrison PM: Generation of functional CD8⁺ T cells by human dendritic cells expressing glypican-3 epitopes. J Exp Clin Cancer Res. 29:482010. View Article : Google Scholar
16	Wang YL, Zhu ZJ, Teng DH, et al: Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation. World J Gastroenterol. 18:2408–2414. 2012. View Article : Google Scholar : PubMed/NCBI
17	Filmus J and Capurro M: Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma. FEBS J. 280:2471–2476. 2013. View Article : Google Scholar : PubMed/NCBI
18	Gao W and Ho M: The role of glypican-3 in regulating Wnt in hepatocellular carcinomas. Cancer Rep. 1:14–19. 2011.PubMed/NCBI
19	Qi XH, Wu D, Cui HX, et al: Silencing of the glypican-3 gene affects the biological behavior of human hepatocellular carcinoma cells. Mol Med Rep. 10:3177–3184. 2014.PubMed/NCBI
20	Wang YF, Kunda PE, Lin JW, et al: Cytokine-induced killer cells co-cultured with complete tumor antigen-loaded dendritic cells, have enhanced selective cytotoxicity on carboplatin-resistant retinoblastoma cells. Oncol Rep. 29:1841–1850. 2013.PubMed/NCBI
21	Huls MH, Figliola MJ, Dawson MJ, et al: Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells fromperipheral and umbilical cord blood. J Vis Exp. 72:e500702013.
22	Wang Y, Shen Z, Zhu Z, et al: Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT: AFP, GPC3 mRNA for prediction of HCC. Hepat Mon. 11:195–199. 2011.PubMed/NCBI
23	Wang YL, Zhang YY, Zhou YL, et al: T-helper and T-cytotoxic cell subsets monitoring during active cytomegalovirus infection in liver transplantation. Transplant Proc. 36:1498–1499. 2004. View Article : Google Scholar : PubMed/NCBI
24	Wayteck L, Breckpot K, Demeester J, et al: A personalized view on cancer immunotherapy. Cancer Lett. 352:113–125. 2014. View Article : Google Scholar
25	Ascierto PA, Kalos M, Schaer DA, et al: Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res. 19:1009–1020. 2013. View Article : Google Scholar : PubMed/NCBI
26	Fu SJ, Qi CY, Xiao WK, et al: Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection. Surgery. 154:536–544. 2013. View Article : Google Scholar : PubMed/NCBI
27	Xu C, Yan Z, Zhou L and Wang Y: A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 139:1417–1424. 2013. View Article : Google Scholar : PubMed/NCBI
28	Ruan J, Liu F, Chen X, et al: Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line. Int J Mol Med. 28:497–503. 2011.PubMed/NCBI
29	Chen IP, Ariizumi SI, Nakano M, et al: Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy. J Gastroenterol. 49:117–125. 2014. View Article : Google Scholar :
30	Zhu AX, Gold PJ, El-Khoueiry AB, et al: First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 19:920–928. 2013. View Article : Google Scholar : PubMed/NCBI
31	Sawada Y, Yoshikawa T, Fujii S, et al: Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: an autopsy case. Hum Vaccin Immunother. 9:1228–1233. 2013. View Article : Google Scholar : PubMed/NCBI
32	Tada Y, Yoshikawa T, Shimomura M, et al: Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide. Int J Onco. 43:1019–1026. 2013.
33	Thanendrarajan S, Nowak M, Abken H, et al: Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one? Leuk Res. 35:1136–1142. 2011. View Article : Google Scholar : PubMed/NCBI
34	Artusio E, Hathaway B, Stanson, et al: Transfection of human monocyte-derived dendritic cells with native tumor DNA induces antigen-specific T-cell responses in vitro. Cancer Biol Ther. 5:1624–1631. 2006. View Article : Google Scholar : PubMed/NCBI
35	Landi A, Babiuk LA and van Drunen Littel-van den Hurk S: High transfection efficiency, gene expression, and viability of monocyte-derived human dendritic cells after nonviral gene transfer. J Leukoc Biol. 82:849–860. 2007. View Article : Google Scholar : PubMed/NCBI
36	Zhang Q, Wang L, Luo C, et al: Phenotypic and functional characterization of cytokine-induced killer cells derived from preterm and term infant cord blood. Oncol Rep. 32:2244–2252. 2014.PubMed/NCBI
37	Sun Z, Shi L, Zhang H, et al: Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer. Clin Immunol. 138:23–32. 2011. View Article : Google Scholar
38	Guo DW, Zhang SY, Hou XZ, et al: Glypican3 in genetically modified human monocyte-derived dendritic cells induced specific cytotoxity against glypican3 overexpressing human hepatocellular carcinoma cells in vitro. Saudi Med J. 29:1235–1240. 2008.PubMed/NCBI